Is transscleral cyclophotocoagulation with diode laser (TSCPC) still a valid option for refractory glaucoma? A real-world single-centre Italian experience

Abstract

Background: To describe our experience with TSCPC with diode laser for refractory glaucoma in a single centre in southern Italy. Methods: This retrospective descriptive study included 134 eyes with refractory glaucoma. Patients underwent TSCPC using a Cyclo-G6 laser method with a G-probe delivery system. Intraocular Pressure (IOP) and the number of Antiglaucoma Medications (AGM) were recorded at baseline and at 1-, 7-, 30-, 60-, 90- and 180-days post-treatment. TSCPC success rate was defined as an IOP between 5 and 21 mmHg or 30% reduction from baseline at the last visit (180 days) [26,27]. Statistical analysis was performed using Graph Pad Prism. Results: IOP decrease of 30% or more from baseline was achieved in 77.6% of eyes at day 1, 100% at 90 days and 85% at 180 days. A reduction in AGM was recorded for 85% of patients. No statistical difference in IOP reduction and number of AGM was found between female and male population at 180 days. No severe complications were reported, and minor complications occurred in 4/134 treated eyes (3%). Conclusions: In our experience TSCPC lead to an lowering of IOP in selected cases and it is still a valid option in the treatment of refractory glaucoma.